Back to search results

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Glioblastoma, IDH-Wildtype · Progressive Astrocytoma, IDH-Mutant, Grade 4 · Progressive Glioblastoma · Progressive Gliosarcoma · Recurrent Astrocytoma, IDH-Mutant, Grade 4 · Recurrent Glioblastoma, IDH-Wildtype · Recurrent Gliosarcoma · Resectable Astrocytoma · Resectable Glioblastoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Mayo Clinic in Rochester, Rochester, Minnesota, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
    Contact: Principal Investigator (Jian L. Campian, MD, PhD)
Study leads

  • Jian L Campian, MD, PhD

    Principal Investigator

    Mayo Clinic

View source on ClinicalTrials.gov(opens in a new tab)